Kyowa Kirin to end distribution of Fareston (toremefine) in the United States

Kyowa Kirin (TSE: 4151) has announced the discontinuation of Fareston (toremefine) 60 mg tablets distribution in the United States, effective August 31, 2024.

Rhea-AI Summary

Kyowa Kirin (TSE: 4151) has announced the discontinuation of Fareston (toremefine) 60 mg tablets distribution in the United States, effective August 31, 2024. This decision aligns with the company's Vision for 2030, focusing on novel therapies. The last order date is set for August 29, 2024, at 2:00 pm CT. Kyowa Kirin has notified the FDA and Orion , the manufacturer of toremefine tablets, about this change. For inquiries, stakeholders can contact specialty.channel.us@kyowakirin.com.

Positive

• Alignment with company's Vision for 2030
• Strategic focus on novel therapies development

Negative

• Discontinuation of Fareston distribution in the US market
• Potential loss of revenue from Fareston sales

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PRINCETON, N.J., Aug. 23, 2024 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, is announcing that it will no longer distribute or fulfill orders for Fareston (toremefine) 60 mg tablets in the United States, effective August 31, 2024. This decision aligns with the company's Vision for 2030 and its focus on the discovery, development and delivery of novel therapies for patients. Kyowa Kirin has previously taken steps to notify the Food and Drug Administration (FDA) and the manufacturer of toremefine tablets, Orion Corporation, of these plans.

The last day for order placement will be August 29th, 2024, 2:00pm CT. Questions may be referred to specialty.channel.us@kyowakirin.com. 

About Kyowa Kirin 
Kyowa Kirin aims to discover and deliver novel treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, focusing on bone/mineral, intractable hematological diseases/hemato oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe.

You can learn more about the business of Kyowa Kirin at: www.kyowakirin.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/kyowa-kirin-to-end-distribution-of-fareston-toremefine-in-the-united-states-302229571.html

SOURCE Kyowa Kirin

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Kyowa Kirin stop distributing Fareston in the US?

Kyowa Kirin will stop distributing Fareston (toremefine) 60 mg tablets in the United States effective August 31, 2024.

What is the last date to place orders for Fareston from Kyowa Kirin?

The last day for order placement of Fareston from Kyowa Kirin is August 29, 2024, at 2:00 pm CT.

Why is Kyowa Kirin (KYKOY) discontinuing Fareston distribution?

Kyowa Kirin is discontinuing Fareston distribution to align with its Vision for 2030 and focus on the discovery, development, and delivery of novel therapies for patients.

Who is the manufacturer of Fareston (toremefine) tablets?

The manufacturer of Fareston (toremefine) tablets is Orion